Senior Investigator Contact Dr. Richard Pratley Dr. Richard Pratley is Senior Investigator at the TRI and the Medical Director of the AdventHealth Diabetes Institute. He is also a professor and faculty member at the Sanford-Burnham Medical Research Institute at Lake Nona in Orlando, Florida. Dr. Pratley has served as Head of the Diabetes and Metabolism Unit of the National Institutes of Health Clinical Diabetes and Nutrition Section in Phoenix, Arizona, leading the push for nationally funded studies in diabetes and metabolic diseases. He then took a position as Senior Director in the Cardiovascular and Metabolism Therapeutic Area at Novartis Pharmaceuticals where he worked on the clinical development of new drugs for diabetes. Afterward, from 2004 to 2011, Dr. Pratley was the Director of University of Vermont’s Diabetes and Metabolism Translational Medicine Unit and a professor at their College of Medicine. There he led many large-scale investigations, including NIH and pharmaceutical company sponsored studies. As a member of the American Diabetes Association, the European Associations for the Study of Diabetes and The Obesity Society, Dr. Pratley continues his active involvement in the professional community. The Henry Christian Award for Excellence in Clinical Research from the American Federation for Clinical Research Foundation was awarded in recognition of his work. He regularly presents at national and international meetings, has written over 150 peer-reviewed articles and is a Principal Investigator for both NIH and pharmaceutical company sponsored trials in diabetes and obesity. He is on the editorial boards of The Lancet: Diabetes and Endocrinology, The Journal of Clinical Endocrinology & Metabolism and the Journal of Diabetes and Complications; and acts as an ad hoc reviewer for many journals, including American Journal of Cardiology, Diabetes Care and Diabetes. Dr. Pratley is a graduate of Wayne State University School of Medicine in Detroit, Michigan, and trained in internal medicine from the University of Michigan in Ann Arbor. He gained further experience in geriatrics and gerontology at the University of Michigan, Johns Hopkins University, and the National Institutes of Health (NIH) National Institute on Aging in Baltimore, Maryland. His current research interests include the prevention of diabetes, improving the care for persons with diabetes, developing new drugs to treat and prevent diabetes and its complications and understanding the role of the fat cell in increasing the risk for diabetes and heart disease. Selected Publications: Pratley RE, Urosevic D, Boldrin M, Balena R, and for the T-emerge 6 Study Group (2012). Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulfonylurea or sulfonylurea-metformin therapy: a randomised, double-blind study (T-emerge 6). Diabetes Obes Metab. 2013 Mar 15(3):234–240. PMID: 22958426. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, Pratley RE, Swift CS. Diabetes in Older Adults. Diabetes Care. 2012 Dec;35(12):2650-64. PMID: 23100048. Tharp WG, Lee YH, Greene SM, Vincellete E, Beach TG, Pratley RE. Measurement of altered AβPP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR. J Alzheimers Dis. 2012;29(2):449-57. PMID: 22258516 Jumpertz R, Guijarro A, Pratley RE, Mason CC, Piomelli D, Krakoff J. Associations of Fatty Acids in Cerebrospinal Fluid with Peripheral Glucose Concentrations and Energy Metabolism. PLoS One. 2012:7(7):e41503. PMID: 22911803. Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M, for the 1860-LIRA-DPP-4 Study Group. Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial. Diabetes Care. 2012 Oct;35(10):1986-1993. PMID: 22851600. Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, Dienz O, Irvin CG, Dixon AE.Obesity and Asthma: An Inflammatory Disease of Adipose Tissue Not the Airway. Am J Respir Crit Care Med. 2012 Oct 1;186(7):Call598-605-PMID : 22837379 Tharp WG, Lee YH, Greene SM, Vincellete E, Beach TG, Pratley RE. Measurement of Altered AβPP Isoform Expression in Frontal Cortex of Patients with Alzheimer’s Disease by Absolute Quantification Real-Time PCR. J Alzheimers Dis. 2012 29(2):449-57. PMID: 22258516 Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; for the BARI 2D Investigators. Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2011 Aug 9;124(6):Call695-703-Epub 2011 Jul 18. PMID: 21768545. Dixon AE, Pratley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, Garudathri J, Raymond D, Poynter ME, Bunn JY, Irvin CG. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011 Sep;128(3):508-15.e1-2. Epub 2011 Jul 23. PMID: 21782230. Jaworski DM, Sideleva O, Stradecki HM, Langlois GD, Habibovic A, Satish B, Tharp WG, Lausier J, Larock K, Jetton TL, Peshavaria M, Pratley RE. Sexually Dimorphic Diet-Induced Insulin Resistance in Obese Tissue Inhibitor of Metalloproteinase-2 (TIMP-2)-Deficient Mice. Endocrinology. 2011 Apr;152(4):1300-13. Epub 2011 Feb 1. PMID: 21285317. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE and Davies M, for the 1860-LIRA_DDP_4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet. 2010 Apr:375(9724):1447-56. PMID: 20417856. Pratley R, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. J Am Geriatr Soc. 2009 Nov;57(11):2011-9. Epub 2009 Sep 30. PMID: 19793357. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009 Oct;25(10):2361-71. PMID: 19650752. Lee YH, Martin JM, Maple RL, Tharp WG, Pratley RE. Plasma Amyloid-beta Peptide Levels Correlate with Adipocyte Amyloid Precursor Protein Gene Expression in Obese Individuals. Neuroendocrinology. 2009;90(4):383-90. Epub 2009 Aug 12. PMID: 19672057. D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.Treatment with the DPP-4 inhibitor Vildagliptin improves fasting islet-cell function in subjects with Type 2 diabetes. J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. Epub 2008 Oct 28. PMID: 18957505. Tharp WG, Lee YH, Maple R, Pratley RE. The cannabinoid CB1 receptor is expressed in pancreatic δ-cells. Biochem Biophys Res Commun. 2008 Aug 8;372(4):Call595-600-Epub 2008 May 27. PMID: 18505678. Lee, YH, Tharp WG. Maple R, Nair S, Permana PA, Pratley RE. Amyloid precursor protein expression is upregulated in obesity. Obesity (Silver Spring). 2008 Jul;16(7):1493-500. Epub 2008 May 15. PMID: 18483477.